Additional analysis on Phase 2 trial of Deucravacitinib (Tyk-2 inhibitor) in PsA. n=203 (dose 6mg QD v 12mg QD v Placebo)
🔹Prior-TNF vs TNF-naive: similar
Significant improvement:
🔹ACR 20/50/70 & HAQ-DI
🔹TJC/SJC/enthesitis
https://t.co/RV1zLpkUQe
#ACR21 Abst#1820 @RheumNow
Links:
Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in…
https://bit.ly/3qtgYLf
10-11-2021